Racura Oncology Secures Ethics Approval for Pivotal Phase IIb/III Leukaemia Trial
Racura Oncology has received ethics approval to begin its pivotal Phase IIb/III trial for RC220, a leukaemia treatment, with patient enrolment expected in…

Racura Oncology has received site ethics approval from the Sheba Medical Center in Israel to initiate the EMILI Phase IIb/III clinical trial. The study evaluates the efficacy of RC220, a proprietary bisantrene formulation, as a treatment for patients with relapsed or refractory acute myeloid leukaemia (R/R AML). The primary objective is to induce remission, thereby enabling patients to proceed to allogeneic haematopoietic stem cell transplantation.
Site activation is scheduled for completion by the end of 2026, with the first patient enrolment and treatment projected for the first quarter of 2027. The company intends to expand the trial to additional sites across Europe, the United States, and Australia throughout 2027, contingent upon regulatory approvals and site feasibility. The Phase IIb stage is fully funded by existing cash reserves.
Racura Oncology
The trial design incorporates a dose-finding component for the Phase IIb stage, which will enrol up to 68 patients. This approach aligns with the US Food and Drug Administration’s Project Optimus initiative, which prioritizes identifying an optimal dose balance between efficacy and toxicity over the traditional maximum tolerated dose model. Interim analyses are planned to determine if the optimal dose can be identified prior to the full completion of the Phase IIb stage.
Following the Phase IIb stage and subsequent regulatory consultations, the trial will transition into a randomized Phase III study. This stage will compare the selected dose of RC220 against the current standard-of-care therapy. The primary endpoint for the Phase III portion is defined as the achievement of remission combined with eligibility for stem cell transplantation. Previous studies conducted at the Sheba Medical Center using an earlier formulation of bisantrene provided the foundational data for the current trial design, though these results are not predictive of the EMILI trial's final outcomes.
More stories
- Dietitians advise small swaps for plant-based eating
- TikTok dementia videos mislead in 66.4% of sample, researchers say
- Aberdeen Royal Infirmary faces police inquiry call over 19 deaths
- Bariatric surgery group loses 28.2% after GLP-1 use
- TOFA boosts mouse energy use 18% while preserving muscle
- ICO probes NHS therapy notes accessible to up to 140,000 staff
- Europe faces 35,000 drug-resistance deaths a year
- U.S. faces loss of measles elimination status after 5,412 cases
Latest news
- David Parr House to honor Victorian art-workman with blue plaque
- Iran's attacks hit 25 tankers near Strait of Hormuz
- FCC approves prison cellphone jamming despite 2.5-mile warning
- Russia strikes Ukraine as Odesa faces electricity strain
- Bahrain reports two injuries after Iranian aerial attacks
- Congress tests Black Democrats' growing policy influence
- Baltic responders fight Sparta II fire after drone strike
- Europe faces attribution gap after 16 cyber, physical incidents

